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Abstract In contrast to leukocyte migration through blood
vessels, trafficking via lymphatic vessels (LVs) is much less
well characterized. An important cell type migrating via this
route is antigen-presenting dendritic cells (DCs), which are
key for the induction of protective immunity as well as for the
maintenance of immunological tolerance. In this review, we
will summarize and discuss current knowledge of the cellular
and molecular events that control DC migration from the skin
towards, into, and within LVs, followed by DC arrival and
migration in draining lymph nodes. Finally, we will discuss
potential strategies to therapeutically target this migratory step
to modulate immune responses.
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Introduction
Vaccination is considered one of the greatest public health
achievements of the twentieth century and has contributed to a
dramatic decline in mortality from infectious diseases.
Antigen-presenting dendritic cells (DCs) are an important
immune cell type that is activated during both vaccination
and infection. Upon encountering a pathogen or a vaccine in
peripheral tissues, DCs take up antigen, mature, and start to
migrate via afferent lymphatic vessels (LVs) to draining LNs
(dLNs), where they present the antigen to T cells for the
induction of adaptive immune responses. Since their discov-
ery approximately 40 years ago [1], ample evidence has
demonstrated the importance of DCs not only in the induction
of adaptive immunity in the context of vaccination and infec-
tion but also for the maintenance of tolerance [2–4]. The
recognition of the importance of DCs in the immune system
was also prominently highlighted by the awarding of the 2011
Nobel Prize of Physiology and Medicine to the late Ralph
Steinman “for his discovery of the dendritic cell and its role in
adaptive immunity” [5].
Although the migratory pattern of DCs from peripheral
tissues to draining LNs has been known for approximately
30 years, many details about the cellular and molecular events
that govern DC migration via afferent LVs are only now
starting to be unraveled. This is very much in contrast to
leukocyte trafficking through blood vessels (BVs), which
has been studied in greater detail over the past 30 years. The
gap in knowledge can likely be attributed to the fact that also
the lymphatic vascular system as a whole has been much less
well studied in comparison to the blood vascular system.
Although LVs were already described in the seventeenth
century, and the embryonic development of lymphatics was
extensively studied during the beginning of the twentieth
century [6], the lack of specific molecular markers for long
time hampered further investigation of the lymphatic vascular
system. In fact, lymphatic markers, such as the vascular en-
dothelial growth factor receptor-3 (VEGFR-3), the
hyaluronan receptor LYVE-1, podoplanin (gp38), or the
lymphatic-specific transcription factor Prox-1 have only been
identified over the past 18 years [6, 7]. Their discovery has
contributed to a true renaissance and explosion of lymphatic
vascular research and to recent progress made in the field of
leukocyte trafficking via LVs.
In this review, we will first give a brief introduction to LV
and DC biology. We will particularly focus on the skin and
skin-dLNs, as these are the organs in which DC migration via
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LVs has mainly been studied. In a next step, we will introduce
some of the tools, which are commonly used to experimen-
tally study DC migration via LVs in vivo. We will then
summarize and discuss different aspects of DC migration in
the order of the DC’s physiologic itinerary, namely its migra-
tion from peripheral tissues towards, into, and within lymphat-
ic vessels (LVs), followed by its arrival and migration in the
dLN. Finally, we will discuss emerging experimental and
clinical approaches to modulate DC migration for the im-
provement of DC-based vaccines or for the prevention of
transplant rejection.
Characteristic features of afferent LVs
The lymphatic vascular system is essential for fluid drainage
from peripheral tissues, and for the uptake of dietary fats in the
intestine [8]. Moreover, it fulfills important immune functions
by mediating the transport of soluble antigens to dLNs as well
as leukocyte trafficking to and from LNs. With the exception
of the brain, LVs are present in virtually all vascularized
tissues. The afferent lymphatic network begins in form of
blind-ended lymphatic capillaries, which are considerably
wider than BVs. Lymphatic capillaries then merge into
collecting vessels, which may span long distances and finally
connect the afferent lymphatic network with a dLN (Fig. 1a).
Afferent LVs connect with the collagen-rich capsule of the LN
and drain lymph directly into the space below the capsule,
which is known as subcapsular sinus (SCS). The bottom of the
SCS is lined by LYVE-1+-positive lymphatic endothelial cells
(LECs), which are interspersed with CD169+ macrophages.
After passing through the SCS, lymph flows into the surface-
rich and highly branchedmedullary sinus. In the paracortex, in
proximity to high endothelial venules (HEVs) and the T cell
area, blind-ended LYVE-1+ cortical sinuses begin and repre-
sent the sites of lymphocyte egress from LNs [9]. Like the
SCS, also the cortical sinuses merge with the medullary sinus,
which finally converges into an efferent LV that exits the LN
[10] (Fig. 1a). Particularly in larger mammals, lymph is often
transported sequentially through many LNs that are organized
in chains. In this setup, an efferent LV can at the same time
represent the afferent LV of the subsequent LN [11]. In this
review, however, we will explicitly refer to the initial LVs in
peripheral tissue, which are composed of both capillaries and
collectors, when mentioning the term afferent LVs. After
passing through one or several LNs, the collecting LVs finally
merge in the thorax to form a single conduit named thoracic
duct, which releases its content (i.e., lymph) into the blood
vascular circulation at the level of the left subclavian vein.
The morphology of afferent LVs is ideally adapted to their
function, namely the uptake and transport of tissue fluids and
leukocytes: Blind-ended lymphatic capillaries are surrounded
by a very thin and highly fenestrated basement membrane,
which is composed of collagen IV, laminin, perlecan, and
nidogen [12, 13] (Fig. 1a). LECs in lymphatic capillaries have
a unique oak leaf shape [14]. Neighboring oak leaf-shaped
LECs partially overlap and are connected to each other by
discontinuous cell–cell junctions (Fig. 1b), which are arranged
in “button-like” associations of adhesion molecules. Such
buttons contain vascular endothelial cadherin and tight
junction-associated molecules such as claudin-5, occludin, or
junctional adhesion molecule-A [14]. This unique pattern of
tight junctions and partially overlapping LECs generates char-
acteristic flaps (also called primary valves), which are permis-
sive to the passage of fluids and macromolecules [14]. More-
over, the flaps are thought to be the prime site where leuko-
cytes enter into LVs [12, 14] (Fig. 1b). While lymphatic
capillaries are ideally suited for the uptake of lymph compo-
nents, lymphatic collectors are uniquely adapted to the trans-
port of lymph: Similarly to endothelial cells in BVs, LECs in
collecting LVs adopt an elongated shape and are surrounded
by a continuous lining of cell–cell junctions, which renders
the collecting LVs less fluid-permeable [14] (Fig. 1a, b).
Collecting LVs also contain specialized valves that impede
retrograde lymph flow and divide the vessel into segments,
which are called lymphangions (Fig. 1a). Compared to lym-
phatic capillaries, lymphatic collectors are surrounded by a
much thicker and less fenestrated layer of basement mem-
brane. Moreover, lymphatic collectors are covered by smooth
muscles cells, which account for the rhythmical contractions
of collecting vessels. These contractions mediate the propa-
gation of lymph from one lymphangion to the next, in down-
stream direction.
CCL21 expression
A molecule with key relevance for DC migration via LVs is
the chemokine CCL21, which is constitutively expressed by
LVs [15–17] (Fig. 2a, b). In response to activating stimuli,
tissue-resident DCs upregulate the CC-chemokine receptor 7
(CCR7) [2, 18], which initiates their migration towards
CCL21-expressing LVs and to dLNs. Indeed, in mice, block-
ade of CCL21 [15] or genetic deletion of CCR7 [19, 20] was
shown to severely compromise DC migration to dLNs.
CCL21 comprises a highly positively charged C-terminal
motif, which accounts for its immobilization on heparan sul-
fates present on cell surfaces or in the extracellular matrix
(ECM) surrounding BVs and LVs [17, 21, 22]. Moreover,
CCL21 was shown to bind with nanomolar affinity to LEC-
expressed podoplanin, a mucin-type glycoprotein [23]. In
mice, CCL21 is encoded by two genes, which give rise to
two gene products: CCL21-Leu and CCL21-Ser differ in only
one amino acid but display gross differences in their tissue
distribution [24]. CCL21-Leu is the main isoform expressed
by LVs [24], whereas CCL21-Ser is mainly expressed by
HEVs and fibroblastic reticular cells (FRCs) in secondary
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lymphoid organs (SLOs) [25]. Substantial insights into these
expression patterns and their functional consequences have
come from the analysis of a naturally occurring mutant mouse
strain, the so-called plt (paucity of lymph node T cells) mice.
plt mice have a defect in the production of CCL19 (the second
ligand of CCR7) and CCL21-Ser but retain expression of
CCL21-Leu in peripheral LVs [24, 26]. As a result, DCs in
plt mice are still able to enter into dermal afferent LVs, but
their entry and interstitial migration in the dLN are impaired
[25, 26].
Dendritic cells
DCs are important immune sentinels that form a functional
bridge between innate and adaptive immunity. Being particu-
larly abundant in tissues, which form the border with the
environment—such as the skin, intestinal tissues or the respi-
ratory tract—DCs readily come into contact with pathogens or
other noxious stimuli that breach the body’s barriers. DCs are
highly phagocytic and derive their name from the fact that
they posses many dendritic process [1], which allow them to
constantly sample their environment. They express a plethora
of receptors that are able to recognize pathogen-associated
molecular patterns, including Toll-like receptors (TLRs) and
RIG and Nod-like receptors. Moreover, DCs can be indirectly
activated by recognition of damage-associated molecular pat-
terns or by inflammatory cytokines produced in the context of
tissue inflammation [2]. DC activation initiates a series of
phenotypic changes that are summarized as maturation [2].
During the maturation process, DCs cleave ingested antigen
into peptides for presentation on major histocompatibility
complex molecules and also upregulate co-stimulatory mole-
cules, which are essential for the subsequent activation of
naive CD4+ and CD8+ T cells. Besides enhancing the antigen
presentation capacity of DCs, maturation also induces pro-
found changes in the DC’s migratory behavior. Importantly,
DCs downregulate inflammatory chemokine receptors and
upregulate CCR7 and CXCR4 chemokine receptors [18].
While DC migration is strikingly enhanced in the presence
of infection and other forms of tissue inflammation, also a
minor but constant migration of DCs to LNs occurs in
uninflamed, steady-state conditions. In fact, steady-state DC
migration was shown to be important for the maintenance of
Fig. 1 Structure of afferent LVs and the LV network in dLNs. a Afferent
LVs begin as blind-ended capillaries, which merge into collecting vessels
and connect with dLNs. In contrast to lymphatic collectors, lymphatic
capillaries have a thin and a highly fenestrated basement membrane
(BM ). Lymphatic collectors are surrounded by smooth muscle cells
(SMCs ) and contain valves. A lymphangion (LA) is defined as the
segment between two valves. The lymphatic network in the dLN is
organized into the subcapsular sinus (SCS), the medullary sinus (MS),
and the cortical sinuses (CS). Further abbreviations used: T cell zone
(TCZ); B cell follicle (BF), efferent lymphatic vessel (ELV). b LECs in
lymphatic capillaries are oak leaf shaped and display a discontinuous,
“button-like” distribution of junctional adhesion molecules (red dots).
Adjacent oak leaf-shaped LECs partially overlap, thereby creating open
flaps, which are also called primary valves. LECs in lymphatic collectors
have an elongated shape and are connected by continuous, “zipper-like”
cell junctions (red lines)
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peripheral tolerance [27, 28]. In particular, mice that lack the
CCR7 receptor have been shown to develop symptoms of
autoimmunity in various organs [29].
DCs present in peripheral organs like the skin do not form a
homogenous population but exist in many different subsets of
functionally related cells [2, 4, 30]. In the skin, the organ in
which DC migration has been best studied, DCs can be very
rudimentarily divided into Langerhans cells (LCs), which are
found in the epidermis, and the various DC subsets present in
the dermis [31, 32] (Fig. 3a–c). LCs developmentally origi-
nate from the bonemarrow (BM) but have the capacity to self-
renew in the epidermis under steady-state conditions [33].
However, under inflammatory conditions, new BM-derived
cells are recruited to the epidermis and differentiate into LCs
[34]. LCs are characterized by the expression of CD207/
langerin, epithelial cell adhesion molecule (EpCAM) and
CD1a [32]. Both in mice and in humans, the dermis is popu-
lated by various subsets of DCs that are referred to as dermal
DCs. Under steady-state conditions, murine dermal DCs are
replaced approximately every 10–14 days by precursors from
the BM [4]. In the context of inflammation, the dermal DC
pool is additionally increased by recruited inflammatory
monocytes that can differentiate into monocyte-derived DCs
[4]. Simply spoken, dermal DCs can be divided into two
subsets, depending on their expression of CD207/langerin
and CD103, or the expression of CD11b [4, 35]. All skin-
resident DC subsets can migrate to LNs, but the exact contri-
bution of the individual subsets to immune responses is not yet
completely understood [4, 35, 36].
Tools to study DC migration in vivo
Experiments to investigate the involvement of a gene product
in DC migration to dLNs rely on the availability of knock-out
mice or blocking antibodies. Traditionally, such experiments
have involved the adoptive transfer of DCs into recipient mice
[37–41], or the performance of so-called fluorescein isothio-
cyanate (FITC) painting experiments [16, 41–44]. In adoptive
transfer studies, DCs are typically isolated from donor mice or
generated in vitro from BM cultures. Upon fluorescent or
radioactive labeling, DCs are injected into the skin, e.g., the
footpad of a recipient mouse, and their arrival in the dLNs is
analyzed and quantified 16–48 h later. In FITC painting
experiments, on the other hand, FITC dissolved in dibutyl
phthalate is applied onto the skin of mice. FITC is a contact
sensitizer and rapidly penetrates the skin, leading to its uptake
by skin-resident LCs and dermal DCs. The painting process
also induces DC mobilization to dLNs, where DCs are subse-
quently quantified based on their green fluorescent signal.
More recently, also confocal- and multiphoton-based time-
lapse microscopy [45] has started to become a useful tool for
elucidating DC migration via LVs. In contrast to the above-
mentioned migration experiments, which address the overall
involvement of a molecule in the migratory process, imaging
studies allow the investigation of DC migration in situ and
with cellular resolution. Consequently, imaging experiments
identify the step in the migratory process a particular candi-
date gene participates in, i.e., whether this is in the migration
towards, into, or within afferent LVs, or migration within
Fig. 2 Expression of CCL21 in
LVs. The expression of CCL21
(green) in LYVE-1+ LVs (red)
was analyzed in tissue whole
mounts prepared from murine ear
skin. a Staining of the
extracellular fraction of CCL21
(performed under unfixed
conditions, as described in [17])
reveals a diffuse CCL21 staining
pattern that largely co-localizes
with LYVE-1+ LVs. b Staining
performed under PFA-fixed and
permeabilizing conditions (as
described in [16]) suggests the
presence of punctuate,
intracellular deposits of CCL21 in
LECs. Scale bar, 100 μm
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dLNs. Time-lapse microscopy experiments to study DC mi-
gration via LVs have been performed in vitro in dermal tissue
explants [12, 13, 17]. Moreover, intravital microscopy (IVM)
experiments performed in the skin and LNs of anesthetized
mice have been reported [43, 46–48]. Both setups rely on the
simultaneous fluorescent visualization of LVs and DCs in the
tissue. In the case of DCs, this has either been accomplished
by imaging endogenously fluorescent DCs in transgenic re-
porter mice [43, 46, 47] or by imaging in vitro-generated
fluorescent DCs after their injection into the tissue in vivo
[43, 46, 48] or application onto dermal tissue explants in vitro
[12, 13, 17]. Similarly, LVs have been visualized by
performing imaging in gene-targeted mice expressing a fluo-
rescent protein in LVs [43] or by labeling LVs in situ with
injected fluorescent antibodies [12, 13, 17, 46–48].
Interstitial DC migration
The migratory behavior of DCs in the dermis appears to
greatly differ from the one of LCs in the epidermis. This can
likely be attributed to the vast differences in the cellular
composition and density between these two compartments.
LCs exhibit numerous dendritic processes that closely inter-
mingle with neighboring epidermal keratinocytes [47, 49]
(Fig. 3a, b), and a rate limiting step in LC migration appears
to be their detachment from keratinocytes. The mechanisms
that govern LC detachment are not well known, but this step
was recently shown to depend on the expression of the adhe-
sion molecule EpCAM [50] and the upregulation of CXCR4,
which directs LCs towards dermal sources of CXCL12 [51].
Moreover, matrix metalloproteinases have been implicated in
LC migration from the epidermis and across the dense epider-
mal basement membrane, which separates the epidermis from
the dermis [52, 53]. Thus, LC migration in the epidermis
appears to be largely regulated by adhesive interactions with
neighboring cells, i.e., with keratinocytes. By contrast, DC
migration in the dermis, which displays a much lower cellular
density, is less restricted to cell–cell adhesive contacts. In fact,
under steady-state conditions, DC migration from the dermis
to the dLN was shown to occur completely independent of
integrin-mediated cell adhesion [13]. DC migration in the
dermis—but also in other tissues like SLOs—is generally
described as an amoeboid-type of migration [54]. This type
of movement predominantly occurs independently of the mo-
lecular composition of the tissue and allows the cell to migrate
autonomously through the interstitial space, without the need
of following preformed routes [54].
Molecules involved in ameboid DC migration
Rather than utilizing adhesive interactions, ameboid move-
ment is achieved by “squeezing and flowing” of the actin
cytoskeleton [54]. This process is generally characterized by
two events taking place at the cellular front and rear: while F-
actin polymerization at the front leads to the formation of
protrusions in forward direction, actomyosin-mediated con-
tractions in the rear support uropod detachment, nuclear con-
traction, and propulsion of cytoplasmic matter [54]. Actin
polymerization is mediated by Rac1 and Rac2, and DCs
deficient in the latter enzymes were shown to display a round-
ed up phenotype and were unable to migrate from skin to
dLNs in vivo [55]. More recently, other molecules involved in
actin cytoskeleton remodeling have been shown to be impor-
tant for DCmigration in vivo, namely the Rho GTPase family
member cdc42 [56], the actin capping protein eps8 [57], and
the Wiskott–Aldrich syndrome protein [58]. Actomyosin-
mediated cellular contraction, on the other hand, is particularly
relevant when cells need to squeeze through narrow openings,
as present in the ECM, or for transmigration through endo-
thelial cell–cell junctions, which require contraction of the
cell’s bulky nucleus [59]. This process is mainly driven by
members of the non-muscle-myosin II family. Although sev-
eral kinases reportedly regulate non-muscle myosin II activity
Fig. 3 Morphology of LCs and DCs in murine skin. a Schematic
representation of the epidermis and dermis: Langerhans cells (LCs) and
keratinocytes (KCs) are shown in the epidermis and dermal DCs and an
afferent LV in the dermis. BM, basement membrane. b , c Visualization of
b Langerhans cells (green) and c dermal dendritic cells (green) and LVs
(red) in the skin of transgenic mice expressing yellow-fluorescent protein
(YFP) under the control of the CD11c promoter [108]. Confocal images
were acquired in whole mounts prepared from murine ear skin, which
were additionally stained with the LV marker LYVE-1 (red). Scale bars
are 20 μm (b) and 50 μm (c)
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[59], so far only the Rho-associated protein kinase (ROCK)
was shown to impact DC migration: IVM experiments per-
formed by our group revealed that pharmacologic blockade of
ROCK significantly reduced the velocity of interstitial migra-
tion of DCs in ear skin and the overall process of DC migra-
tion to dLNs [43].
Insights from IVM
Important new insights into the behavior and migration of
DCs in the skin have recently emerged from IVM experiments
[47, 49, 60]. These analyses have, for instance, revealed that
under steady-state conditions, LCs are immotile in compari-
son to the significantly more motile dermal DCs [47, 49]. In
contrast to the numerous dendritic processes of LCs, dermal
DCs display fewer but thicker dendrites, which they use to
actively probe the environment [47, 60]. One IVM study
reported that upon encountering a pathogen (Leishmania ma-
jor ) or a danger stimulus (LPS), dermal DCs rapidly became
immotile, retracted their dendritic processes, and only
regained motility after 6–8 h [60]. By contrast, another study
reported that DCs becamemore motile as early as 20 min after
exposure to a contact sensitizer or to various adjuvants and
started to migrate directedly towards LVs [47]. LC mobiliza-
tion in response to inflammatory stimuli or physical trauma,
on the other hand, appears to only occur 24–48 h after stim-
ulation [47, 49]. This is in line with recent studies demonstrat-
ing that, upon stimulation with contact sensitizers, LCs arrive
at significantly later time points in dLNs as compared to
dermal DCs [49, 61]: While the arrival of dermal DCs peaked
around 24 h after sensitization, LCs only started to arrive
several days after sensitization [49, 61].
Role of CCL21
Time-lapse microscopy has also contributed to a better under-
standing of how interstitially migrating DCs approach LVs.
Specifically, time-lapse microscopy experiments revealed that
the directedness, but not the velocity of interstitial DC migra-
tion, was dependent on G-protein-coupled receptor signaling
[60], in particular on CCR7 [17, 46]. Thus, while wild-type
DCsmoved directedly towards LVs, CCR7−/−DCs only rarely
reached LVs by random migration [17, 46]. Current data
regarding the pattern of CCL21 distribution and DC chemo-
taxis towards LVs are still somewhat controversial. One recent
study reported on the existence of punctuate extracellular
CCL21 deposits in the perilymphatic basement membrane,
which DCs reportedly used as docking sites prior to
intravasation into LVs [46]. Other findings suggest that extra-
cellular CCL21 displays a rather diffuse staining pattern,
which largely co-localizes with and surrounds LVs [17]
(Fig. 2a). Interestingly, stainings performed under
permeabilizing conditions have revealed that a great
proportion of CCL21 is present within LECs, in intracellular
stores that belong to the trans-Golgi network [16, 17, 62]
(Fig. 2b). In support of the existence of a peri-lymphatic
CCL21 gradient, ex vivo time-lapse microscopy revealed that
DCs in vicinity of less than 100 μm of a LV started to increase
the directedness of their migration towards the LV [17]. More-
over, the latter study showed that directed DC migration
towards LVs depended on the immobilization of CCL21 on
heparan sulfates, which are present on the LEC surface or in
the surrounding basement membrane: treatment of dermal
tissue explants with heparitinase abolished the perilymphatic
extracellular CCL21 staining pattern and eliminated directed
migration of DCs towards LVs [17]. Similarly, DC migration
to dLNs was shown to be reduced in mice with an endothelial-
specific defect in heparan sulfate synthesis, further indicating
that heparan sulfates are important for the establishment of a
peri-lymphatic CCL21 gradient [22].
Role of other molecules
Besides CCL21, also CCL19, the other known ligand of
CCR7, has been implicated in DC migration to dLNs. In
contrast to CCL21, CCL19 lacks a positively charged C-
terminal moiety and therefore is exclusively found in a soluble
form in tissues [21]. Interestingly, CCL19 does not appear to
be expressed in LECs, but is produced by activated DCs. It has
been suggested that, due to interstitial flow, DC-produced
CCL19 might act in an autocrine manner by directing DC
migration into the direction of fluid drainage, i.e., towards
draining LVs. However, this concept of “autologous chemo-
taxis” [41] still awaits conclusive in vivo proof.While an early
study observed that antibody-mediated blockade of CCL19
reduced DC migration from skin to dLNs [63], no migration
defect was recently reported for CCL19-deficient mice [64].
Another chemoattractant with a well-documented role in DC
migration via LVs to dLNs is the endogenous lipid mediator
sphingosine-1-phosphate (S1P). S1P is well known for its
indispensible role in directing lymphocytes egress from LNs
into efferent LVs [10]. Maturation was shown to upregulate
S1P receptors (S1PRs), in particular S1PR1 and S1PR3, in
DCs, and to induce their chemotaxis towards S1P [65, 66].
Moreover, S1P receptor 1 (S1P1)
−/− DCs as well as DCs in
mice treated with the S1P analog FTY720 displayed reduced
migration from skin to dLNs [65, 66]. In LNs, LECs have
been identified as an important source of S1P, thereby estab-
lishing the S1P gradient between nodal tissue and lymph,
which guides egressing lymphocytes [67]. Although not for-
mally shown, it is conceivable that a similar gradient exists
between the interstitial space in peripheral tissues and lymph
and therefore could support directed DC migration towards
afferent LVs. Alternatively, S1P could be important for keep-
ing DCs within LVs, once they have transmigrated into the LV
lumen.
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DC transmigration across lymphatic endothelium
DC transmigration across lymphatic endothelium has tradi-
tionally been investigated in in vitro experiments performed
with cultured LEC monolayers. In a typical setup, LECs are
grown to confluence in transwell inserts and DC transmigra-
tion towards a chemotactic stimulus present in the lower well
is assessed [42, 44, 62, 68]. A general drawback of in vitro
transmigration experiments might be the fact that LEC mono-
layers in vitro form continuous, zipper-like cell–cell junctions
that resemble the junctional arrangement in lymphatic collec-
tors [14] (Fig. 1b), whereas DC immigration into LVs report-
edly occurs through the button-like cell junctions present in
LV capillaries [12, 14]. Nevertheless, in vitro assays have
identified various molecules involved in the transmigration
process, namely the LEC-expressed adhesion molecules
CD31 [69], CD99 [69], VCAM-1 [42], ICAM-1[42], and
L1CAM [44] (Fig. 4b). Many of these molecules were subse-
quently validated in in vivo migration experiments [42, 44] or
in DC crawl-out experiments performed with human skin
explants [69, 70].
Insights from IVM
AlsoDC transmigration into lymphatic capillaries has recently
been investigated by time-lapse imaging experiments. Exper-
iments performed in murine ear skin explants [12] have re-
vealed that DCs first need to penetrate the thin and discontin-
uous basement membrane that surrounds lymphatic capil-
laries. Transmigration preferentially occurs through
preexisting pores. These pores get widened during the trans-
migration process, thereby facilitating the subsequent passage
of more DCs through the same portal [12]. Once in direct
contact with the lymphatic endothelium, DCs transmigrate
into the LV lumen by passing through the characteristic flaps
present between oak leaf-shaped LECs in lymphatic capil-
laries (Fig. 1b). The flaps generate openings of approximately
2–3 μm in diameter, which DCs appear to traverse without
altering the “button”-like pattern of tight junctions between
neighboring LECs [12, 14]. Besides experiments performed in
skin explants, DC transmigration into the LVs has also been
investigated by IVM: upon arrival at the LV, DCs were ob-
served to dock and probe the vessel surface for several mi-
nutes, followed by transmigration into the vessel lumen [46,
47]. Also during IVM, DCs were frequently observed to
successively transmigrate at the same point into the LV lumen,
possibly through the same portal and flap [43, 46]. Further-
more, IVM experiments revealed that the entire transmigra-
tion process takes between 30 and 60 min [43, 46, 47]. It is
currently not clear whether DCs may also enter LVs in vivo by
migrating through zipper-like junctions of lymphatic collec-
tors. Notably, the basement membrane of collecting vessels
was shown to be thicker and less fenestrated [12], which
additionally might render transmigration into collectors more
difficult.
Involvement of integrins
In agreement with the fact that migration of adoptively trans-
ferred, integrin-deficient DCs from uninflamed skin to dLNs
was not compromised [13], time-lapse microscopy experi-
ments did not detect any defect in the entry process of
integrin-deficient DCs into afferent LVs [13]. Thus, under
uninflamed, steady-state conditions, DC entry into LVs does
not require integrins. Intriguingly, various studies have, how-
ever, revealed that in the context of inflammation, DC and LC
migration was compromised in mice deficient for ICAM-1,
the ligand of the DC-expressed integrins Mac-1 (αMβ2) and
LFA-1 (αLβ2), or in mice treated with ICAM-1 or LFA-1
blocking antibodies [39, 42, 71]. These controversial findings
most likely are explained by the fact that LECs in uninflamed,
steady-state skin express extremely low levels of ICAM-1 and
VCAM-1, whereas these molecules are strongly upregulated
in the context of inflammation [16, 43]. Indeed, performing a
side-by-side comparison of DC migration from inflamed and
from uninflamed tissues, a recent study demonstrated that
blockade of LFA-1 only reduced DC migration from inflamed
but not from uninflamed skin [39]. Notably, in contrast to
LECs found in uninflamed skin in vivo [16, 43], in vitro
cultured LECs express high basal levels of VCAM-1 and
ICAM-1, which are further induced upon treatment with
inflammatory cytokines [42]. In vitro studies also revealed
that ICAM-1 and VCAM-1 form enriched structures in in-
flamed LECs, which facilitated the adhesion and transmigra-
tion of DCs across the lymphatic endothelium [39].
Further molecules involved in transmigration
Although afferent lymphatic capillaries contain open flaps,
which are thought to facilitate leukocyte entry and fluid flow,
the lymphatic vasculature nevertheless appears to pose a
physical barrier to immigrating leukocytes. Similarly to ex-
travasation out of BVs, also DC transmigration into LVs
appears to depend on actomyosin-mediated contraction of
the cell’s bulky nucleus [40, 43, 72]. This process could on
one hand be needed for squeezing through the narrow pores in
the basement membrane that surrounds LVs [12] (Fig. 1a).
Alternatively, nuclear contraction could be required for the
passage through the endothelial flaps, where the approximate
diameter of 2–3 μm likely still represents a barrier that cannot
be passed without active cellular contraction [59, 73]
(Fig. 1b). In support of this assumption, the axonal guidance
molecule semaphorin 3A (Sema3A), which is highly
expressed in LVs but not in BVs, was recently shown to
mediate DC transmigration across lymphatic endothelium
[72]. The authors demonstrated that Sema3A production in
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LECs promoted actomyosin-mediated cellular contraction in
DCs, thereby enhancing DC transmigration across lymphatic
endothelium. Consequently, DC migration to dLNs was sig-
nificantly reduced in Sema3A−/− mice or in mice deficient in
plexin-A1, which together with neuropilin-1 forms the
Sema3A receptor on DCs [72]. On the other hand, also the
C-type lectin CLEC-2, which is upregulated on mature DCs,
was shown to promote actin cytoskeleton rearrangements and
to support DC transmigration into LVs [40]. The cellular
ligand of CLEC-2 on LECs during this process is the small
transmembrane glycoprotein podoplanin, a well-known lym-
phatic marker gene [6]. CLEC-2 deficiency impaired DC
migration on podoplanin substrates in vitro, as well as DC
migration into LVs and to dLNs in vivo [40].
Involvement of CCL21
Besides attracting DCs towards LVs, CCL21 has also been
implicated in DCmigration on cellular substrates and hence in
transmigration across lymphatic endothelium. CCL21
immobilized on the surface of FRCs was recently shown to
support haptotactic movement of DCs by triggering integrin-
mediated adhesion [74]. Moreover, CCL21 was shown to
enhance DC transmigration across in vitro-cultured lymphatic
endothelium in an ICAM-1-dependent manner [62]. However,
given the fact that LECs in vivo in uninflamed tissues express
much lower ICAM-1 levels, the supportive role of CCL21 in
mediating DC transmigration across ICAM-1-expressing
LECs is likely only relevant in the context of tissue
inflammation.
Impact of inflammation-induced changes in LECs on DC
migration
In addition to inducing the upregulation of the integrin ligands
ICAM-1 and VCAM-1, tissue inflammation and inflammato-
ry mediators have also been shown to induce the expression of
CCL21 and other chemokines in LECs [16, 37, 39, 42, 62].
Furthermore, it was shown that increased lymph flow, which
typically accompanies inflammatory processes, can upregu-
late CCL21 and ICAM-1 levels in LECs [68]. It has been
suggested that an inflammation-induced increase in CCL21
expression could contribute to the enhancement of DC migra-
tion, which is typically observed in the context of
Fig. 4 Model of DC migration
towards, into, and within afferent
LVs. a (1) DCs approach LVs in a
CCR7/CCL21-dependent
manner. (2) Transmigration
across the lymphatic endothelium
occurs through the characteristic
flaps present in lymphatic
capillaries. (3) Once within
lymphatic capillaries, DCs
actively crawl towards
downstream collecting vessels,
(4) from where they are passively
transported to the dLN by flow. b
Schematic summary of molecules
shown to mediate DC migration
across lymphatic endothelium
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inflammation [16, 37, 62]. Indeed, in vitro studies have re-
vealed that inflammatory cytokines like TNFα enhance the
secretion of CCL21 from its intracellular stores [62], but is still
not clear how tissue inflammation affects CCL21 secretion
in vivo. When comparing DC migration in two different
models of tissue inflammation, our group recently observed
that a higher upregulation of lymphatic CCL21 and ICAM-1,
which was observed in one of the models, did not actually
correlate with a higher induction of DC migration [16]. Thus,
it seems more likely that the ability of an inflammatory stim-
ulus to promote DC maturation and to increase the DC’s
responsiveness for CCR7 ligands is the rate-limiting factor
in DC migration to dLNs.
Although many other chemokine are upregulated in LECs
in the context of tissue inflammation [16, 42], only CXCL12
[75] and CX3CL1[38] have thus far been implicated in DC
migration to dLNs. Inflammation-induced CXCL12 was
shown to enhance themigration of CXCR4-expressing dermal
DCs and LCs to dLNs [75]. Moreover, LEC-expressed
CX3CL1 (fractalkine) reportedly supports DC transmigration
across lymphatic endothelium and the overall trafficking pro-
cess from inflamed tissue to dLNs [38]. On the other hand,
experiments performed with CCR7−/−DCs also have revealed
that in the context of tissue inflammation DC migration to
LNs remains highly CCR7-dependent [16]. Overall, these
data indicate that CCR7 remains the key mediator of DC
migration during inflammation, but that other chemokines like
CXCL12 and CXCL3 contribute to this process, possibly by
affecting distinct steps in the migration cascade.
Intralymphatic DC migration
Recent IVM experiments from three different groups, includ-
ing our own, have revealed that DCs that have transmigrated
into lymphatic capillaries are not passively transported away
by lymph flow, but actively crawl inside lymphatic capillaries
[43, 46, 47]. These findings contrast with previous IVM data
from rat mesenteric lymphatic collectors; in these experi-
ments, leukocytes were observed to be passively propagated
as rounded-up cells [76, 77]. Different from mesenteric
collecting LVs, in which peak flow velocities of several
millimeter/second can be reached [78, 79], intralymphatic
flow velocities in capillaries reportedly range from 1 to
30 μm/s [80, 81]. The observation that DCs actively crawl
in lymphatic capillaries therefore suggests that the intra-
capillaric hydrodynamic forces might not be sufficient to
support passive drainage of cells right upon entry into the
blind-ended capillaries. IVM also revealed that DCs detach
and flow once within collecting vessels [43, 46], in line with
the notion that lymph flow is stronger in collecting vessels. On
the other hand, detachment in collectors could also be attrib-
uted to differences in adhesion molecule expression between
the capillary and the collecting vessel bed, respectively. In
support of this hypothesis, we have observed by FACS anal-
ysis performed on skin single cell suspensions that ICAM-1
levels were consistently higher in LECs from lymphatic cap-
illaries as compared to LECs from lymphatic collectors (data
not shown). Although intralymphatic DCs displayed an over-
all movement in the direction of downstream LNs, IVM
studies indicated that intralymphatic DCs frequently change
direction and also crawl for some time in the opposite direc-
tion of the presumed lymph flow [43, 46]. It is presently not
clear what determines the directionality of DC migration
within lymphatic capillaries. In agreement with a previous
study [46] we observed that upon PBS injection into the skin,
to artificially enhance lymphatic flow, DCs migrated more
directed within lymphatic capillaries [43]. However, in addi-
tion to more directed migration in downstream direction (i.e.,
towards the dLN), DCs also migrated more directed into the
opposite, upstream direction, resulting in no net improvement
of DC migration into the downstream direction of the dLN
[43]. Thus, it is presently not clear to which extent direction-
ality of intralymphatic DC crawling is determined by lymph
flow or whether other signals, such as for example chemical
cues deposited within LVs, might play a role in this process.
Molecules involved
Thus far, intralymphatic crawling of DCs has only been
scarcely studied at the molecular level. Performing IVM, we
have identified a role for ROCK in DCs in this process. As
previously mentioned, ROCK initiates actomyosin-mediated
nuclear contractions, which are important when DCs migrate
through narrow openings, as present in the ECM of the
interstitium in vivo [43]. Moreover, ROCK was also shown
to mediate leukocyte crawling within BVs, since it facilitates
de-adhesion of integrins from their endothelial cell-expressed
ligands, in particular from ICAM-1 [73]. Interestingly,
intralymphatic DC crawling was only weakly ROCK-
dependent under steady-state conditions. By contrast, block-
ade of ROCK profoundly inhibited intralymphatic DC migra-
tion in the context of tissue inflammation, likely by inhibiting
de-adhesion from inflammation-induced ICAM-1 [43]. The
fact that under steady-state conditions integrin ligands like
ICAM-1 are only weakly expressed in LVs [16, 43] and that
intralymphatic crawling was only weakly ROCK dependent
[43] supports the notion that also intralymphatic DCmigration
under steady-state conditions does not require integrins [13].
Nevertheless, it is well possible that other LEC- and DC-
expressed cell surface molecules support intralymphatic DC
adhesion and crawling: in this regard, molecules such as
Sema3A and podoplanin, which thus far have mainly been
implicated in the transmigration process [40, 72], could be
interesting candidates. Overall, the observation that
transmigrated DCs first crawl in lymphatic capillaries and
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are only later on passively drained by flow indicates that this
migratory step is more complex than previously appreciated.
DC migration across the lymphatic sinus of dLNs
Only few studies have thus far investigated the arrival and
migration of DCs in dLNs. Experiments performed in plt
mice, which lack expression of CCR7 ligands in LNs, have
revealed that the process of DC migration into the LN T cell
area is highly dependent on the expression of CCR7 ligands
by FRCs of the T cell zone [25, 26]. DC translocation into the
T cell area was also shown to be integrin independent, since
adoptive transfer of WT and integrin-deficient DCs into the
skin resulted in no differences in the localization and number
of cells in the Tcell areas of the dLN [13]. Further insights into
the entry process of DCs into the nodal tissue have recently
come from IVM experiments performed in popliteal LNs,
which drain the skin of the footpad [48]. Upon injection into
afferent LVs, DCs were observed to penetrate into the LN by
crossing lymphatics at the level of subcapsular sinus. Surpris-
ingly, this was in contrast to injected CD4 T cells, which
preferentially entered the node across medullary sinuses
[48]. The entrance and migration towards the T cell area was
observed to completely depend on CCR7 expression [48].
Similarly, in vitro time-lapse microscopy performed on LN
sections revealed that DCs migrated in a CCR7-dependent,
directed manner from the LN periphery towards the Tcell area
[74]. CCL21 deposited on FRCs supported haptotactic DC
migration, but the directionality of DC movement was deter-
mined by soluble chemokine gradients. Interestingly, the latter
study also revealed that DCs in contact with surface-bound
CCL21 can enzymatically cleave off its C-terminal heparan
sulfate-binding moiety, thereby generating a soluble form of
CCL21 [74]. While surface-bound CCL21 enhances cell mi-
gration along fibers or cellular scaffolds by triggering integrin
activation and cell adhesion, truncated CCL21 can form sol-
uble gradients that contribute to DC chemotaxis [74].
Inflammation is known to increase DC migration to dLNs
[16, 37]. Interestingly, recent evidence suggests that this pro-
cess might not only be regulated by changes occurring in DCs
and in afferent LVs but also by modulation of the lymphatic
network in the dLN. In particular lymphangiogenesis occur-
ring in the SCS of LNs draining sites of inflammation was
shown to partially account for the increase in DC migration
observed in the context of inflammation [82, 83]. In a model
of inflammation induced by CFA injection into the skin, DC
accumulation in dLNs could be significantly reduced by anti-
lymphangiogenic treatment [82]. DCs that have migrated
from a peripheral tissue to a dLN typically remain in this node
and do not exit via efferent LVs or migrate to further dLNs
[11, 48]. Besides their prominent role in antigen presentation,
also additional functions have recently been identified for DCs
within dLNs. Constitutive homing of DCs to dLNswas shown
to contribute to LN homeostasis by controlling the phenotype
of HEVs and the capacity of this specialized vascular bed to
recruit lymphocytes [11, 84, 85]. In specific, activation of
lymphtoxin beta receptor signaling in HEV endothelial cells
by DC-expressed lymphotoxin was shown to induce the ex-
pression of functional trafficking molecules in HEVs, thereby
contributing to lymphocyte homing [84].
Modulation of DC migration for therapy
Enhancing DC migration during vaccination
Over the last 20 years, there has been a great interest in
targeting DCs for the development of therapeutic vaccines,
in particular for the treatment of cancer [3]. Many of these
vaccination approaches follow the classical vaccination
scheme in which antigen and adjuvants are injected into the
patient. At the same time, also many DC-based vaccines are
currently being investigated [3]. The latter typically involve
the generation of DCs from blood-derived monocytes or from
CD34+ hematopoietic precursors, DC maturation and loading
with tumor antigens, followed by DC injection into the patient
[3, 86]. The first marketed cancer vaccine is Sipuleucel-T, a
cell-based vaccine that was FDA-approved for the treatment
of metastatic prostate cancer in 2010 [87]. Sipuleucel-T is
generated from antigen-presenting cells derived from the pa-
tient’s blood, which are cultured in presence of a fusion
protein consisting of the DC maturation factor GM-CSF and
the prostate cancer antigen prostate acid phosphatase. After
culture, the cells are intravenously injected into the patient—a
route of administration that is expected to preferentially target
DCs to the spleen and peripheral organs like the liver or lung,
but not directly to LNs [88]. Besides intravenous administra-
tion, other vaccination approaches involve injection of DCs
into the skin [86, 88, 89] or directly into LVs or LNs [86], to
enable immune priming in LNs. The route of administration
continues to be a matter of debate and is thought to affect the
quality of the Tcell response induced as well as the trafficking
behavior imprinted onto the effector T cells [86].
Imaging studies in patients injected intradermally with
radiolabeled DCs have indicated that only a very small frac-
tion of injected DCs, ranging from 1 to 8 %, typically arrives
in dLNs [86, 89, 90]. This low number is similar to what is
typically observed when performing adoptive transfer exper-
iments in mice [37–39]. Consequently, several experimental
approaches to enhance DC migration via LVs have recently
been pursued. Given that the CCR7/CCL21 axis is of key
importance for DC migration, a particular focus has been on
enhancing CCR7 expression and CCR7 responsiveness in
DCs. Lipid-based mediators, namely prostaglandin E2
(PGE-2) [91], leukotriene C4 [63], and leukotriene B4 [92],
270 Semin Immunopathol (2014) 36:261–274
have recently been shown to enhance DC migration to LNs,
by increasing CCR7 expression levels and DC responsiveness
for CCR7 ligands. In fact, one of the most commonly used
maturation protocol for clinical grade DCs involves the incu-
bation of monocyte-derived DCs in media supplemented with
proinflammatory cytokines and prostaglandin E2 [93]. How-
ever, in contrast to the above mentioned studies, other studies
have indicated that PGE-2 might negatively affect the
immune-stimulatory capacity of DCs [94]. Interestingly, it
was recently suggested that this might not be the case when
maturing DCs in presence of leukotriene C4 [92]. Besides
addition of lipid mediators, generation and maturation of DCs
in presence of interferon alpha (IFNα) was shown to enhance
DC migration in vitro and in vivo, by enhancing CCR7
expression and responsiveness, as well as DC adhesion and
transmigration across lymphatic endothelium [95, 96]. Inclu-
sion of IFNα during DC maturation has recently started to be
investigated in clinical trials [97]. In addition to the manipu-
lation of DCs to enhance their responsiveness for CCL21
ligands, also preconditioning of the skin prior to DC injection
may augment DC migration to LNs. For example, in mice,
inflaming the skin by local injection of TNFα was shown to
enhance DC migration to dLNs, presumably by upregulating
CCL21 expression in LVs [37]. Moreover, in mouse models
as well as in human cancer patients, it was shown that induc-
tion of skin inflammation by topical application of the TLR7
agonist imiquimod prior to s.c. injection of immature DCs
promoted DC maturation and subsequent migration to dLNs
[98, 99].
Blocking DC migration to prevent transplant rejection
DC migration via LVs to dLNs may not only be a therapeutic
target for boosting vaccination but also for modulating immu-
nity in the context of transplant rejection [100]. Over the last
10 years, numerous studies have documented the involvement
of inflammatory lymphangiogenesis in the graft rejection
process [23, 83, 101, 102]. Blockade of lymphangiogenesis
and, consequently, of the migration of graft-derived DCs to
dLNs has been proposed as a potential approach for
prolonging graft survival. This might be particularly attractive
in the context of transplanted tissues like the cornea, which
normally is avascular and only becomes infiltrated with blood
and LVs under inflammatory conditions. In fact, in mouse
mode ls of cornea t ransplan ta t ion , b lockade of
lymphangiogenesis was shown to decrease DC migration
from the graft to dLNs and to strongly increase allograft
survival [101, 102]. Similarly, anti-lymphangiogenic treat-
ment with sunitinib or VEGFR-3-blocking Abs promoted
survival of pancreatic islets allografts transplanted under the
kidney capsule [103]. Besides blocking lymphangiogenesis,
also direct manipulation of DC trafficking from the allograft,
by targeting the CCL21/CCR7 axis, has been investigated as a
potential strategy for prolonging graft survival. For example,
in plt mice, the survival of islet allografts implanted under the
kidney capsule was significantly prolonged [104]. Similarly,
when islets allografts were cultured in medium containing
CCL21 prior to transplantation, to induce the emigration of
DCs from the graft, allograft survival was nearly doubled
[105]. Moreover, treatment of mice with CCL19-Ig fusion
protein enhanced the survival of kidney and cardiac allografts,
likely by perturbing the migration CCR7-expressing DCs and
T cells into SLOs as well as their co-localization within SLOs
[106]. On the other hand, no prolongation of graft survival
was observed in the context of cardiac allografts transplanted
into plt mice or of islet allografts implanted into the liver of plt
mice [104]. Thus, overall, approaches targeting DC migration
have yielded varying results, depending on the type of organ
transplanted and the site of grafting. An important confound-
ing factor in these studies likely is the fact that LVs are not the
only route by which DCs can emigrate from transplanted
tissues: graft-derived antigen-presenting cells were also
shown to induce alloresponses in the spleen, upon exiting
the graft via BVs [100, 105, 107]. Therefore, blockade of
DC migration via LVs will only proof to be a therapeutically
useful strategy for those transplant situations, in which DC
trafficking via lymphatics indeed represents the prime route
for host sensitization.
Conclusions
Over the past 15 years, major progress has been made in our
understanding of DC migration from peripheral tissues to
dLNs. It is very clear by now that DC migration via lym-
phatics is not a random event but a tightly regulated process,
in which CCL21/CCR7 signaling plays a dominant role. In
fact, the CCR7/CCL21 axis was shown to be important for
almost every step in DC migration via LVs; namely for DC
migration towards and into afferent LVs and also for DC entry
into the dLN and migration into the nodal T cell area. Another
important recent insight to the field has been the discovery that
DC migration via LVs in steady-state does not require
integrins. By contrast, integrins are involved in DC migration
in the context of inflammation, when integrin-ligands are
induced on lymphatic endothelium. Most of the recent ad-
vances in our understanding of DC migration via LVs have
come from in vitro and in vivo imaging experiments. The
latter make it possible to study DC migration in situ and with
cellular resolution. Besides many other new insights, IVM has
revealed that DCs, which have entered into afferent LVs,
actively migrate within lymphatic capillaries and are only
passively transported by flow once they reach lymphatic
collectors. In the future, it will be relevant to understand
whether this behavior is only dictated by the hydrodynamic
conditions in the vessel or whether intralymphatic DC
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migration might have further biologic significance. Overall,
the recent findings have revealed that DCmigration via LVs is
a by far more complex process than previously assumed. A
major challenge for the years to come will be to optimally use
the emerging knowledge about DCmigration for the improve-
ment of immune-modulatory therapies.
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